Dexcom stock forecast 2025 based on current P/E ratios and

Based on current P/E ratios and projected earnings growth, Dexcom stock forecast 2025 could justify a valuation range of $120-$150 under bullish market conditions. Whilst the FDA cited deficiencies at the facilities, it has not told Dexcom to stop producing, marketing, manufacturing or distributing products. There is also no mention of any device recall requirements, meaning patient access to products should not be hindered. DXCM expects adjusted gross margin to be approximately 62%. Adjusted operating margin is projected to be approximately 21%. For growth investors, Dexcom stock forecast 2025 is supported by continued expansion in subscription models, creating steady ARR (Annual Recurring Revenue).